



ERYTECH to Host Third Quarter 2019 Conference Call and Business Update on November 8, 2019

Nov 05, 2019 | Press Releases

LYON, France, Nov. 05, 2019 (GLOBE NEWSWIRE) -- **ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP)**, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Third Quarter 2019 conference call and webcast on Friday, November 8, 2019, at 2:30 PM CET/8:30 AM EST to discuss operational highlights.

The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: **7394954#**

USA/Canada: +1 (833) 818-6807

France: +33 1 70 80 71 53

International Dial-In Number: +1 (409) 350-3501 **United-Kingdom:** +44 2031070289

The webcast can be followed live online via the link: <https://edge.media-server.com/mmc/p/irt7vk6s>

An archived replay of the call will be available for 7 days by dialing + **1 855 859 2056**, Conference ID: **7394954#**.

An archive of the webcast will be available on ERYTECH's website, under the "Investors" section at investors.erytech.com

About ERYTECH and eryaspase: www.erytech.com

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH's primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company's lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell's altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. An investigator-sponsored Phase 2 study in acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

CONTACTS

ERYTECH
Eric Soyer
CFO & COO

NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations

+33 4 78 74 44 38
investors@erytech.com

+33 1 44 71 98 52
erytech@newcap.eu

PDF available at: <http://ml.globenewswire.com/Resource/Download/a4eda10e-975a-47b5-b896-5ca7af6acea5>



Source: Erytech Pharma S.A.